Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Programmed death-1 (PD-1) is a strong negative regulator of T lymphocytes in tumor-microenvironment. By engaging PD-1 ligand (PD-L1) on tumor cells, PD-1 on T cell surface inhibits anti-tumor reactivity of tumor-infiltrating T cells. Systemic blockade of PD-1 function using blocking antibodies has shown significant therapeutic efficacy in clinical trials. However, approximately 10 to 15% of treated patients exhibited serious autoimmune responses due to the activation of self-reactive lymphocytes. To achieve selective activation of tumor-specific T cells, we generated T cells expressing a dominant-negative deletion mutant of PD-1 (PD-1 decoy) via retroviral transduction. PD-1 decoy increased IFN-γ secretion of antigen-specific T cells in response to tumor cells expressing the cognate antigen. Adoptive transfer of PD-1 decoy-expressing T cells into tumor-bearing mice potentiated T cell-mediated tumor regression. Thus, T cell-specific blockade of PD-1 could be a useful strategy for enhancing both efficacy and safety of anti-tumor T cell therapy.
Abstract
Programmed death-1 (PD-1) is a strong negative regulator of T lymphocytes in tumor-microenvironment. By engaging PD-1 ligand (PD-L1) on tumor cells, PD-1 on T cell surface inhibits anti-tumor reactivity of tumor-infiltrating T cells. Systemic blockade of PD-1 function using blocking antibodies has shown significant therapeutic efficacy in clinical trials. However, approximately 10 to 15% of treated patients exhibited serious autoimmune responses due to the activation of self-reactive lymphocytes. To achieve selective activation of tumor-specific T cells, we generated T cells expressing a dominant-negative deletion mutant of PD-1 (PD-1 decoy) via retroviral transduction. PD-1 decoy increased IFN-γ secretion of antigen-specific T cells in response to tumor cells expressing the cognate antigen. Adoptive transfer of PD-1 decoy-expressing T cells into tumor-bearing mice potentiated T cell-mediated tumor regression. Thus, T cell-specific blockade of PD-1 could be a useful strategy for enhancing both efficacy and safety of anti-tumor T cell therapy.
참고문헌 (22)
- Kyi, C., "Checkpoint blocking antibodies in cancer immunotherapy", FEBS Lett, 588, pp.368~376 (2014)
- Henick, B. S., "The PD-1pathway as a therapeutic target to overcome immune escape mechanisms in cancer", Expert Opin. Ther. Targets, 18, pp.1407~1420 (2014)
- Topalian, S. L., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N. Engl. J. Med, 366, pp.2443~2454 (2012)
- Topalian, S. L., "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab", J. Clin. Oncol, 32, pp.1020~1030 (2014)
- Hamid, O., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N. Engl. J. Med, 369, pp.134~144 (2013)
- Philips, G. K., "Therapeutic uses of anti-PD-1and anti-PD-L1 antibodies", Int. Immunol, 27, pp.39~46 (2015)
- Okazaki, T., "PD-1 and PD-1 ligands: from discovery to clinical application", Int. Immunol, 19, pp.813~824 (2007)
- Agata, Y., "Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes", Int. Immunol, 8, pp.765~772 (1996)
- Dong, H., "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", Nat. Med, 5, pp.1365~1369 (1999)
- Latchman, Y., "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat. Immunol, 2, pp.261~268 (2001)
- Ishida, M., "Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues", Immunol. Lett, 84, pp.57~62 (2002)
- Liang, S. C., "Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses", Eur. J. Immunol, 33, pp.2706~2716 (2003)
- Dong, H., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", Nat. Med, 8, pp.793~800 (2002)
- Chemnitz, J. M., "SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation", J. Immunol, 173, pp.945~954 (2004)
- Okazaki, T., "PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine", Proc. Natl. Acad. Sci. U. S. A, 98, pp.13866~13871 (2001)
- Nishimura, H., "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor", Immunity, 11, pp.141~151 (1999)
- Nishimura, H., "Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice", Science, 291, pp.319~322 (2001)
- Muenst, S., "The PD-1", PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy, 2015, pp.19, 201~211
- Naidoo, J., "Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies", Ann. Oncol, 26, pp.2375~2391 (2015)
- Weber, J. S., "Management of immune-related adverse events and kinetics of response with ipilimumab", J. Clin. Oncol, 30, pp.2691~2697 (2012)
- Shin, J. H., "Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models", Blood, 119, pp.5678~5687 (2012)
- Prosser, M. E., "Tumor PD-L1 co-stimulates primary human CD8(＋) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor", Mol. Immunol, 51, pp.263~272 (2012)